Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

Summary

This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS). In this study, olatorepatide is being tested in people with HS and living with overweight or obesity to see if it helps improve their HS symptoms and quality of life and helps support weight loss. The study is looking at: What side effects olatorepatide might cause How well olatorepatide works How much olatorepatide is in the blood at different times If the body makes antibodies to olatorepatide, which may cause olatorepatide to not work as well

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Hidradenitis Suppurativa

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Regeneron Pharmaceuticals

Last updated on ClinicalTrials.gov

November 10, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites